11 May 2022

Scandion Oncology enhances management and clinical development function with appointment of global executive as Chief Medical Officer

Attachments Download report
Dr. Alfredo Zurlo joins Scandion Oncology immediately, bringing decades of experience from clinical development in oncology.

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, significantly ramps up its clinical development capabilities with the appointment of Dr. Alfredo Zurlo as Chief Medical Officer (CMO). Alfredo Zurlo joins Scandion immediately as part of the company’s Executive Management-team.

A medical doctor by training, Alfredo Zurlo has more than 20 years of experience in planning and conducting early and late-stage clinical programs in oncology (cancer). He has held several global management positions in a seven-year long career with Roche, including serving as International Medical Director of Oncology and heading the launch of bevacizumab (Avastin) in Europe and the rest of the world for the colorectal indication.

Following his tenure at Roche, Alfredo Zurlo has served as CMO in the two biotech companies Glycotope and Mologen. In addition to his extensive strategic and operational clinical trial experience, he brings a large international network of health care professionals, research scientists and industry experts to Scandion.

“I am delighted to welcome Alfredo Zurlo to Scandion. As we develop both our company and development pipeline, most notably our lead asset SCO-101, it is critical to further strengthen our capabilities in clinical development. With his experience in the field of cancer drug development, Alfredo is an excellent addition to our team, and he will play a key role in the execution of our clinical trials and the planning of pivotal development”, says Bo Rode Hansen, President & CEO of Scandion.

“Scandion has a tremendous potential to help address cancer’s resistance to existing treatments, which is perhaps the biggest problem in modern cancer treatment. I am excited by the opportunity to join this company and contribute to the development of new treatments to the benefit of patients, their relatives, health care professionals and society”, says Alfredo Zurlo, CMO at Scandion.

Alfredo Zurlo replaces Peter Michael Vestlev, who will continue to work for Scandion in the position of Distinguished Medical Scientist, ensuring an effective handover to Alfredo Zurlo.

For further information please contact:

Mads Kronborg, Head of External Communication

Phone: +45 6051 4955

Email: ir@scandiononcology.com

The information was provided by the contact person above for publication on May 11, 2022 at 12.00 CET.

Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.

Globally, close to 10 million patients die every year from treatment resistant cancers, and our medicines are relevant in several different cancers as oral add-on drugs to existing market leading therapies. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). 

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments Download report